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Abstract Over 20 years ago it was realized that the traditional
methods of the treatment of injuries to joint components: car-
tilage, menisci and ligaments, did not give satisfactory results
and so there is a need of employing novel, more effective
therapeutic techniques. Recent advances in molecular biology,
biotechnology and polymer science have led to both the ex-
perimental and clinical application of various cell types,
adapting their culture conditions in order to ensure a directed
differentiation of the cells into a desired cell type, and
employing non-toxic and non-immunogenic biomaterial in
the treatment of knee joint injuries. In the present review
the current state of knowledge regarding novel cell sources,
in vitro conditions of cell culture and major important bioma-
terials, both natural and synthetic, used in cartilage, meniscus
and ligament repair by tissue engineering techniques are de-
scribed, and the assets and drawbacks of their clinical appli-
cation are critically evaluated.
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Introduction
As a result of ageing populations and the consequent increas-
ing incidence of musculoskeletal disorders, attention has re-
cently been focused on the regeneration of joint structures,
primarily knee joints. This task requires the employment of
novel tissue engineering (TE) techniques necessary to regen-
erate cartilage, menisci, or ligaments [1, 2]. However, the ap-
plication of the TE techniques face numerous challenges, in-
cluding: the appropriate choice of the cell source and the cul-
ture methods used for tissue repair, suitable scaffolds and
proper bioreactors [3, 4].
Among the cell types, which qualify for the repair of dam-
aged joint structures the most suitable are chondrocytes,
fibrochondrocytes, mesenchymal stem cells (MSCs), human
embryonic stem cells (hESCs) and induced pluripotent stem
cells (iPSCs) [5]. The design of a suitable scaffold requires its
proper architecture, which ensures optimal conditions for cell
growth. When the scaffolds are loaded with the appropriately
selected cells, supplied with proper growth factors, subjected
to mechanical stimuli in a suitable bioreactor and implanted
into the injury site, then the intrinsic healing response can
begin [6].
The aim of the present report is to review the current liter-
ature on the cell-based regeneration of knee cartilage, menisci
and ligaments. The review includes in vitro, ex vivo and
in vivo studies as well as clinical trials.
Cell sources
Of the numerous methods available, cell-based techniques are
the most advanced approaches. The cells, first considered suit-
able for transplantation into the lesion site of articular cartilage
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were autologous chondrocytes [7]. The procedure, which was
introduced in an animal model in the early 1980s is called
autologous chondrocyte implantation (ACI). In the early
1990s, Brittberg et al. [7] in their initial clinical studies on
the effectiveness of ACI, reported good or excellent results
in 14 out of 16 patients. Two subsequent clinical trials, con-
ducted in larger groups and longer follow-up terms, showed
good-to-excellent results in 76 % [8] and 88 % [9] of patients
respectively, indicating that the emerging TE technique would
soon replace traditional methods of treatment for cartilage,
menisci and ligaments injuries and more suitable cells would
be searched for.
Chondrocytes and fibroblasts
Autologous chondrocytes, first used for the repair of articular
cartilage injuries, have also been found as a good cell source
for the meniscus tear repair [10]. It has been well-established
that current methods of meniscus repair are only effective in
treating tears located in the vascularized (red-red) zone of the
meniscus, while ruptures of the avascular (white-white) zone
still present a challenge for cell-based therapies [11]. Since
meniscectomy contributes to the premature development of
osteoarthritis (OA) [12], research has turned towards menis-
cus replacement methods that use cell/biomaterial constructs.
The potential advantage of chondrocytes over meniscus cells
is mainly due to the higher production rate of type II collagen
and glycosaminoglycans (GAGs) by chondrocytes [13]. In-
vestigations in animal models have shown that the treatment
of a meniscus rupture within the avascular zone with autolo-
gous chondrocytes provides a good bonding of the lesion bor-
ders [10]. Moreover, it is extremely difficult to obtain a suffi-
cient number of autologous meniscus cells from patients who
have already undergone meniscectomy. For these reasons,
both autologous and allogenic chondrocytes have been used
in the replacement of menisci [14, 15].
Fibroblasts have been used to regenerate ligamentous tis-
sue. Cooper et al. [16] compared four cell sources used for
anterior cruciate ligament (ACL) reconstruction. Cells were
harvested from the ACL, medial collateral ligament (MCL),
Achilles tendon, or patellar tendon. The results showed that
fibroblasts from the Achilles and patellar tendons showed the
highest proliferation rate. However, only the ACL fibroblasts
demonstrated a significantly higher expression of
differentiation-specific ligament genes. Ge et al. [17] found
that fibroblasts derived from ACLs or MCLs produced type
I collagen and α-smooth muscle actin, and did not synthesize
type II collagen. In that study, however, fibroblasts showed a
lower proliferation rate and ability to survive when compared
to mesenchymal stem cells (MSCs). In addition, the use of
fibroblasts is troublesome due to several factors, including:
(i) reduced number of native cells available for implantation,
(ii) cell dedifferentiation in vitro and (iii) the need for an ad-
ditional operation.
Mesenchymal stem cells
The use of MSCs as an alternative source for therapy is ad-
vantageous since the number of cells available for implanta-
tion is much higher, cells differentiate in vitro into desired
cells and there is no need for a second operation. The major
obstacle in the application of MSCs in articular cartilage re-
pair, however, is an uncontrolled process of endochondral
ossification, which may occur after cell transplantation [18,
19]. In several studies commonly used bone marrow-derived
stem cells or stem cells isolated from various tissues were
compared. Pei et al. [20] reported that in MSCs derived from
synovial tissue, potential for endochondral ossification was
lower than in bone marrow-derived MSCs. When, in an ani-
mal model, MSCs were applied to restore full-thickness
osteochondral defects, bone marrow, periosteal and synovial
MSCs showed a higher potential for lesion repair than
adipose-derived and muscle-derived MSCs [21]. Adipose-
derived stem cells, have a low potential for differentiation into
cartilage because they do not express the transforming growth
factor-β (TGF-β) receptor and showed a reduced expression
of bone morphogenetic proteins (BMPs) [22]. Nevertheless,
in cells isolated from the infrapatellar fat pad, the
chondrogenic potential in vitro is similar to that of the MSCs
derived from synovium [23, 24]. A disadvantage in using
bone marrow-derived MSCs is their lower proliferation rate
in the elderly and in the OA patients [25]. The MSCs have
been tested in several different animal species [26, 27] as well
as in clinical studies in humans [28, 29]. The results of these
studies confirm the high chondrogenic potential of MSCs
in vivo and the outcomes were similar to those obtained using
ACI. In order to reach final conclusions, further research in
larger groups of patients is required.
Several researchers have also investigated (in animal
models) the effectiveness of autologous MSC transplan-
tation to repair meniscus tears. The results of those
experiments showed that MSCs implanted into the
avascular area of the meniscal tear proliferate and ex-
pand, thus producing large amounts of ECM compo-
nents and thus accelerating the healing process [30,
31].
MSCs have also been used in ligament regeneration due to
the ability to effectively differentiate into the ligament fibro-
blasts [32]. These cells exhibit the fibroblasts’ phenotype both
in vitro [17] and in vivo [33]. Recent advances in elucidating
the basic molecular mechanisms underlying cell differentia-
tion and signalling pathways involved in this process, together
with the progress in cell homing and implantation techniques
could lead to the application of this method in clinical trials.
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Human embryonic stem cells
In addition to MSCs, other cell types that present
chondrogenic or fibrogenic potential are human embryonic
stem cells (hESCs) and induced pluripotent stem cells
(iPSCs). The first of these, hESCs, derive from human blas-
tocysts and have the potential to differentiate into all three
germ layer cell lines. Over the last several years, various pro-
tocols were used to differentiate hESCs into chondrocytes [34,
35]. Chondrocytes obtained from hESCs show an immature
phenotype; therefore, in order to achieve cell maturation, fur-
ther refinement of this technique applying special biological
and environmental factors as well as biomaterials is required.
The potential of hESCs to differentiate into fibrochondrocyte-
like cells has been investigated by Hoben et al. [36], who
showed that the co-culture of hESCs with chondrocytes or
meniscus cells results in a significant increase in tissue-
specific collagen production. Results from that study have
proven that hESCs are suitable for the repair of the meniscus
with fibrocartilage cells. However, because of legal consider-
ations and ethical controversies, the clinical use of hESCs is
still under consideration.
Induced pluripotent stem cells
Induced pluripotent stem cells are reprogrammed pluripotent
cells, which like hESC, also show the potential to differentiate
into three germ layer cell types. Most human iPSCs derive
from fibroblasts and they are reprogrammed using the forced
expression of transcription factors, which are known onco-
genes [37]. For this reason, the clinical application of iPSCs
is currently being investigated with great caution, given the
high potential for oncogenicity that may result from the use of
these factors [38]. However, it should be noticed that the use
of iPSCs rather than hESCs avoids an ethical issue since the
genetic information contained in iPSCs derives from the pa-
tient’s own genome and is also less likely to induce an im-
mune response [39]. The use of iPSCs in TE is an emerging
field of research, and may lead to a wide range of alternative
methods that can be used in the treatment of injuries of knee
joint structures. Preliminary studies have demonstrated that
iPSCs derived from mouse fibroblasts differentiate towards
chondrocytes, which synthesize ECM components, type II
collagen and GAGs. These chondrocytes, in an in vitro model
of cartilage defects, integrate with the native tissue when im-
planted in agarose scaffolds [25].
Culture conditions
The use of cells expanded under conditions that preserve their
differentiation potential and phenotype is crucial in the cell-
based TE protocols. Cell growth depends on several important
factors, including: temperature, pH, oxygen concentration, nu-
trients, growth factor/cytokine supply, concentration of meta-
bolic waste and culture type (monolayer or 3D) [40]. Typical-
ly, cells are cultured at 37 °C, although some reports suggest
that oxidative stress can be reduced by culturing MSCs at
32 °C [41]. The pH is normally 7.4 and it decreases when
the concentration of metabolic waste products increases in
the medium. This parameter should be carefully controlled,
since major changes in the pH may be detrimental for the cell
culture [42]. Continuous oxygen supply is essential to provide
proper dO2 concentration, which decreases as the biomass
increases. The atmospheric oxygen level, however, may cause
the oxidative stress of the cells, thereby decreasing their via-
bility [43]. It has been reported that MSCs expand more effi-
ciently at 2 %O2 [44, 45], whereas hESCs grow better at 20 to
30 % oxygen levels [46]. Moreover, Foldager et al. [47] dem-
onstrated that oxygen tension (pO2) as low as 9 % in a 3D
culture stimulates the expression of genes that encode
chondrogenic markers (Sox9, aggrecan and Col2a1).
Nutrient supply is obviously crucial at each stage of cell
differentiation. During cell expansion, cell metabolism is
mainly based on energy obtained from glycolysis, whereas
at the differentiation stage, there is a switch to oxidative phos-
phorylation as the energy source [48]. It has been well-
established that chondrocytes dedifferentiate when cultured
in monolayers, whereas they are able to retain their phenotype
in the 3D culture [49]. Cell dedifferentiation results in the
decreased expression of type II, IX and XI collagens, as well
as SOX9 and aggrecan, with a change to Bmore fibroblastic^
collagens such as type I, V collagen and versican [49, 50]. In
large 3D constructions, however, the number and metabolism
of cells located in the inner part decreases [51]. A lower con-
centration of cells in the 3D culture would compromise the
mechanical strength of the implant. However, this problem
can be overcome by applying bioreactors with dynamic fluid
circulation, such as a rotating-wall-vessel bioreactor (RWV)
or stirred-flask bioreactor [52]. To date, no consensus has been
reached concerning optimal cell densities in cell-based thera-
peutic methods. In different reports cell numbers ranged from
2.5 × 105 [53] to 1 × 107 per cm2 [54]. Another study reported
thatMSCs require an even higher cell density during the chon-
drogenesis process [55].
The principal growth factors directing chondrogenesis
and fibrogenesis are members of the TGF-β family [56].
Cell expansion and differentiation are also affected by
bone morphogenetic proteins (BMPs) and the following
growth factors: insulin-like growth factors (IGFs), basic
fibroblast growth factor (bFGF), vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF) and growth and differentiation factors (GDFs)
[53, 57].
Cell culture is labour-intensive, time-consuming and ex-
pensive. Therefore, efforts have been made to optimize this
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procedure by using bioreactors to obtain fully controlled, sta-
ble, automated cell cultures at a reduced cost [42].
Biomaterials used for cartilage, menisci
and ligaments repair
Collagen
Collagen as the major component of cartilage, menisci as well
as the ligaments and ECM has long been used in TE as a
natural biomaterial [58, 59]. Nowadays, a wide range of
collagen-based biomaterials are commercially available. Col-
lagen matrices are characterized by relatively low immunoge-
nicity and a proper structure, which mimic a native tissue
environment, thus preventing cell dedifferentiation. However,
collagen scaffolds are difficult to handle and sterilization may
alter their structure [60]. In collagenmatrices type I collagen is
commonly used. In vitro studies of type I collagen hydrogel
scaffolds has shown that the cells embedded in the hydrogel
easily adhere and proliferate well and the MSCs seeded on
type I collagen matrix, retain their differentiation potential for
a long time. In one of the studies, it was reported that proteo-
glycan and type II collagen content were similar to that ob-
tained by the same number of cells seeded on clinically used
type I/III collagen scaffolds and cultured under the same con-
ditions for 42 days [61]. Yuan et al. [62] demonstrated the
immunomodulatory properties of type I collagen hydrogel.
Chondrocytes cultured in this gel for 14 days increased the
synthesis of both MHC class I and II proteins. These cells
produced ECM components, mainly type II collagen and
GAGs continuously over the culture period. Gierloff et al.
[63] compared the proliferation rate of MSCs and chondro-
genesis using various commercially available collagen and
hyaluronan scaffolds including: non-cross linked bovine type
I matrix, type I/III collagen scaffold, type I collagen sponge
and hyaluronic acid gel. Chondrogenesis mediated by MSCs
was documented by the elevated expression of the SOX-9
gene, chondroadherin, cartilage oligomeric matrix protein
(COMP) and type IX and XI collagens. The cells seeded on
the spongy type I collagen scaffold, showed the highest pro-
liferation rate and number of viable cells (over 54 %) com-
pared to the other two collagen matrices and hyaluronan gel.
The collagen-based meniscus implant (CMI) was the first
technique of this type used for meniscus regeneration [64].
CMI is a resorbable type I collagen scaffold and was
arthroscopically sutured to the remaining parts of the menis-
cus. This technique is recommended for the repair of the outer
parts of the meniscus and is not suitable for the whole tissue
[64]. Martinek et al. [65] conducted an in vitro study in an
animal model using CMI seeded with autologous
fibrochondrocytes. In the experimental group (n=9), the me-
niscus tissue was restored after 3 months. In that group, the
implants were seeded with cells containing a larger ECM vol-
ume, whereas the implants in the control group (non CMI-
seeded) were filled with a high number of cells with a small
ECM volume. Another preliminary study involving eight pa-
tients who were observed for 24 months showed clinical im-
provement in all patients. Macroscopic evaluation during the
second-look arthroscopy revealed tissue regeneration, and his-
tological assessment confirmed the formation of fibrocartilage
[66]. Niemeyer et al. [67] performed a long-term clinical study
to prove the superiority of standardized collagen membrane
over first generation ACI for the treatment of cartilage defects.
Another study, conducted in a group of 160 patients who were
observed for 12 months, supports previous observations. Al-
though clinical improvement was reported in most patients,
the meniscus-like tissue was present in only 50 % of cases
[68]. Pabbruwe et al. [69] investigated another commercially
available type I/III collagen membrane, used as a carrier for
human bonemarrowMSCs, in the treatment of meniscus tears
of the avascular zone. Cell-loaded and cell-free scaffolds were
cultured in vitro on the white zone of ovine menisci. The
MSC-loaded constructs integrated well with the host tissue
and this group showed significantly better results in tensile
strength compared to the acellular constructs.
Gelatin
Gelatin derives from collagen and is a form of denatured col-
lagen fibre. Due to denaturation, gelatine exhibits lower anti-
genicity than the collagen itself, and is biocompatible and
biodegradable. The most commonly used form of gelatine
scaffolds is hydrogel, which is created by fibre crosslinking.
The fibres are degraded enzymatically, with the degradation
time depending on water content [70]. In addition, these scaf-
folds retain the Arg-Gly-Asp (RGD) sequence, which pro-
motes cell adhesion and proliferation. However, the poor me-
chanical properties of gelatine gels preclude the use of this
polymer alone as a cell-carrier in cartilage, meniscus or liga-
ment regeneration [71]. In order to improve the mechanical
strength, in most studies the cross-linked gelatine scaffolds or
multilayer constructs were applied [72, 73]. Lien et al. [72]
studied a multi-layered gelatine-ceramic construct for
osteochondral lesion repair. In the rat model, they showed that
a gelatine layer seeded in vitro with chondrocytes led to the
development of cartilage tissue in less than four weeks. From
the 1st to the 4th week of culture, the GAGs content increased
about 20-times, the cells overgrew the scaffold and filled the
pores, while only a small number of hypertrophic cells were
observed. The same group investigated the influence of gela-
tine scaffolds pore size on rat chondrocyte growth and synthe-
sis of the ECM components. The authors concluded that these
cells secrete more GAGs and overgrow better scaffolds when
the pores are larger (from 250 to 500 μm in size). The authors
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also observed an increase in chondrogenic markers: type I, II
and X collagens, as well as aggrecans [74].
For meniscus regeneration, a gelatine-based, three-layered
scaffold has been developed by Sarem et al. [75]. These au-
thors seeded heterogeneous gelatine/chitosan matrices with
human meniscus cells and, showed increased cell number
and proliferation over the culture time. Moreover, they report-
ed that cells seeded on scaffolds with higher gelatine content
presented a higher proliferation rate and that the biomaterial
was more cytocompatible.
Hyaluronan
Hyaluronan is a polysaccharide polymer most often used for
orthopaedic applications in the form of benzyl ester of
hyaluronic acid (HA). Its degradation process and HA release
has been well-documented [76]. HA is as an important com-
ponent of GAGs, and it shows major chondrogenic and
chondro-protective properties [77, 78], although the clinical
application of non-cross-linked hyaluronan-based scaffold is
limited due to its weak mechanical strength [79]. Hyaluronan
has been used to modify the synthetic PCL (polycaprolactone)
scaffold of proper mechanical strength and has been shown to
improve the distribution and differentiation of chondrocytes
seeded on the PCL scaffolds. Type I and II collagen and
aggrecan synthesis was also increased when the HA-
modified versus an unmodified PCL were used [80]. More
recently, Wu et al. [81] investigated the impact of HA on
chondrogenesis in human adipose-derived stem cells
(ADSCs). Cells were cultured in a 2D monolayer system
using either HA/fibrin or fibrin hydrogels. ECM formation
assessment showed that cells seeded on HA/fibrin gel induced
higher levels of chondrogenic markers expression (SOX-9,
type II collagen and aggrecan). Type II collagen and GAG
synthesis on HA/fibrin gel was also superior to that of fibrin
gel alone. The authors indicated that induction of chondrogen-
esis in the HA-enriched scaffold was due to the HA and
CD44-cell surface receptor involved in HA interactions.
In the TE of the meniscus, HA was used as a scaffold
composite together with gelatine [82], collagen [83, 84] and
PCL [85]. In a rabbit model of meniscus defect, MSCs seeded
on hyaluronan/gelatine matrices and implanted to the injury
site, integrated well with the host tissue, filled the defect and
three months, newly formed fibrocartilage, with hyaline-like
cartilage zones, was observed [82]. In a more recent study,
Zellner et al. [84] compared the effects of repairing meniscus
tears in the avascular zone of rabbits using four different treat-
ment methods: untreated tear, suture of the meniscus, a PRP-
loaded composite and a scaffold loaded with autologous
MSCs. At 12 weeks, no signs of healing were observed in
either the untreated or sutured tear groups. The PRP-loaded
composite resulted in poor tissue regeneration, while the
MSC-seeded scaffold filled the defect with meniscus-like
tissue comprising low cell numbers and high type II collagen
content. Kon et al. [85] investigated hyaluronan/PCL con-
structs with improved mechanical properties to assess their
value as a cell-carrier of autologous chondrocytes. One-year
after surgery, cell-seeded scaffolds showed significantly better
fibrocartilage formation when compared with the cell-free im-
plants and the group that underwent meniscectomy.
Fibrin
Fibrin is generated by the proteolytic cleavage of fibrinogen
by the enzyme thrombin. Since fibrinogen could be formed
f r om th e pa t i e n t s ’ f i b r i n , t h i s b i oma t e r i a l i s
immunocompatible and has been widely used in clinical med-
icine in the form of fibrin glue for cardiovascular, skin, liver,
or muscle repair [86]. The mechanical properties and integrity
of fibrin hydrogels depend on Ca2+ concentrations and the pH.
Similar to gelatine, fibrin scaffolds are characterized by low
mechanical strength and rapid degradation. Fibrin-based scaf-
folds have been used in the TE of cartilage, meniscus and
ligaments, although they are usually modified with the addi-
tion of more resistant polymers [87]. It has been well-
established that fibrin promotes cell proliferation and differ-
entiation [88]. Kreuz et al. [89] investigated the use of
scaffold-assisted ACI to repair focal cartilage defects. In that
study, 52 patients underwent cartilage repair with autologous
chondrocytes embedded in a fibrin scaffold. Four-year clinical
observations showed significant improvement in over 80 % of
patients, with moderate to complete filling of the lesion ob-
served on MRI.
Fibrin hydrogel has also been investigated in meniscal re-
pair [90]. In that study, chondrocytes embedded in the fibrin
scaffold and cultured in vitro bonded to the surrounding tissue
and restored the fibrocartilage, while no tissue formation was
observed in the cell-free constructs.
Silk fibres
Silk fibres are another emerging and attractive alternative to
ECM-derived polymers, mainly due to their outstanding me-
chanical properties, which are crucial for cartilage, meniscus
and ligament regeneration. Silk is a fibrous protein synthe-
sized by several different species of worms, although the
best-characterized and most frequently used fibres are pro-
duced by the silkworm (Bombyx mori) [91]. Silk fibres show
a low immunogenicity and antigenicity, and thus are good
candidates for the use as cell-carriers in the TE [92]. In a rabbit
model of articular cartilage defect, bonemarrowMSCs seeded
on silk/chitosan (SF/CS) scaffolds restored the cartilage sur-
face with smooth and well-integrated newly-formed tissue. In
contrast, in rabbits who received the cell-free scaffold, only a
distinct margin between the native and the regenerated tissue
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was visible. At 12 weeks after surgery, neither group showed
scaffold fibres and no immunogenic reactions occurred [93].
A three-layered silk scaffold has been developed as a cell
carrier for meniscal tear repair [94]. The multi-layered struc-
ture mimics the fibre alignment of a native human meniscus.
The outer parts of silk matrices were seeded with human fi-
broblasts and the central part was loaded with chondrocytes.
At the 28th day of in vitro culture, the cells were evenly dis-
tributed across the three layers. GAGs and type I and II colla-
gens were detected in all parts of the construct. The same
research group also evaluated the use of MSCs seeded on a
multi-layered silk scaffold [95]. In that study, the authors
found that MSCs differentiated into chondrogenic lineages
after four weeks. The cells stained positive for GAGs and
collagen and the differentiated cells showed mature chondro-
cyte phenotype.
Silk fibres have also been used in numerous in vitro and
in vivo studies of ligament regeneration. Liu et al. [96] com-
pared rabbit MSCs and fibroblasts harvested from the ACL
and seeded on silk scaffolds. The results of the in vitro study
showed that MSCs showed a higher proliferation rate, synthe-
sized more ECM components and exhibited the increased ex-
pression of genes encoding type I and II collagen and
tenascin-C. The same group investigated the in vivo effects
of MSCs seeded onto silk scaffolds and used in ACL recon-
struction in the rabbit model [97]. The authors compared two
groups, one which received cell-loaded scaffolds and the other
(control group) receiving acellular scaffolds. In the 24th week,
the cellular scaffolds restored the ACL tissue in the experi-
mental group, while in the control group less of the fibrous
tissue formation with visible silk fibres in the regenerated
ligament were observed. Histological assessment revealed
the intense production of the ECM components, high type I
collagen expression and fibroblast-like morphology of the
cells. In the control group, all samples stained negative for
the ECM components. When converted into a large animal
model and evaluated after 24 weeks, the MSCs seeded on
the silk scaffold differentiated into fibroblasts and their mor-
phology resembled the native tissue. The follow-up study re-
vealed the complete degradation of silk fibres and the regen-
erated ACL was able to withstand nearly 52 % of the maxi-
mum load compared to the native ligament [33].
Synthetic polymers
Synthetic polymers include poly (lactic acid) (PLA), poly
(glycolic acid) (PGA), PLA and PGA copolymer, poly
(lactide-co-glycolide (PLGA) and polycaprolactone (PCL).
PLA is used in two isomeric forms: poly L-lactic acid
(PLLA) [98] and poly DL-lactic acid (PLDLA) [99], both
are biocompatible and biodegradable, with a degradation time
of PLA ranging from one to two years [100]. In vivo, PLA is
subjected to hydrolysis and the degradation rate depends on
the size and shape of implant [101]. Like all synthetic poly-
mers, PLA is easily produced and processed. Polymeric
PLDLA-PCL scaffolds were used to repair meniscal tears in
a rabbit model [102]. In that study, matrices were seeded with
meniscus cells and implanted into the site of the defect. The
results of the cell-loaded and cell-free groups were compared
at 12 and 24 weeks after implantation. In the 24th week, the
tissue that formed in the pre-seeded cell group resembled the
native meniscus, while the cell-free scaffolds failed to restore
the area of meniscus incision and developed fibrosis at the
implantation site. Both the isomeric forms of PLA have been
tested for ligament reconstruction. Cells seeded on the PLLA-
braided scaffold adhere, proliferate and exhibit ECM compo-
nent production after three weeks of culture [16].
PGA degrades to glycine, which enters the tricarboxylic
acid cycle, and is thus metabolized through the natural meta-
bolic pathways [103]. PGA is an FDA-approved polymer that
has long been used in biodegradable sutures. In a pig model
study of articular cartilage defect, autologous chondrocytes
were seeded and implanted (after two weeks of culture) onto
a PGA/PLA scaffold and evaluated after six months [104]. At
the 6th-month after the surgery, the cells completely filled the
site of the defect with mature cartilage-like tissue. In the
newly-formed cartilage, type II collagen and GAG contents
were similar to the surrounding tissue. In contrast, the cell-free
PGA/PLA construct implantation resulted in the formation of
fibrous tissue that did not integrate with the native cartilage,
collapsed into the site of the defect and no synthesis of type II
collagen or GAGs were detected.
Kang et al. [105] reported the regeneration of rabbit menis-
ci using the PGA/PLGA scaffold seeded with allogenic
meniscal cells implanted into the knee joint. At the 10th week,
meniscal regeneration was observed and collagen and PG
content in the newly-formed tissue was similar to that of na-
tive tissue. Saha et al. [106] studied three different cell types
cultured under various conditions in vitro and in vivo on the
PLGA-based scaffolds. Human bone marrow MSCs, human
neonatal chondrocytes and adult chondrocytes were cultured
in the chondrogenic medium on the cartilage phase of a com-
mercial osteochondral scaffold. All cell types revealed a high
proliferation rate, ECM secretion and cell growth. After the
intra-peritoneal implantation of cell-loaded constructs into
nude mice, cells formed a cartilage-like tissue. However, in
both MSCs and neonatal chondrocytes, some fibrocartilage-
like tissue insertions were observed, while the adult
chondrocytes managed to maintain their chondrogenic
phenotype.
The effect of chondrocyte-seeded PLGA scaffold was ex-
amined in meniscal regeneration using porcine meniscal discs
implanted in vivo in a heterotopic mouse [107]. In ten out of
12 samples of PLGA cell-loaded constructs, the newly formed
tissue filled the entire lesion with a fibrous and cartilaginous
tissue, while fibrocartilage was found in seven cases, whereas
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when acellular scaffolds were used, no signs of healing were
observed.
PCL is a soluble polymer with a degradation time of two to
three years [108]. A three-layered heterogeneous PCL scaf-
fold that mimics the fibre organization and alignment of native
tissue has been developed and one of the studies compared
cell attachment, proliferation and differentiation using bovine
chondrocytes seeded either on a homogenous PCL scaffold or
on the three-layered PCL construct. In that study, no differ-
ences in cell adhesion, GAG content, type I and II collagen
production were found [109]. Moutos and Guilak [110] stud-
ied an anisotropic PCL/fibrin gel scaffold seeded with human
ADSCs. Although cells cultured for 28 days under
Bchondrogenic^ conditions synthesized the ECM compo-
nents, the phenotype of the cells was fibrocartilage-like.
Conclusions
Combining various types of cells, including stem cells, with
new biomaterials presents enormous possibilities to engineer
the damaged tissues, including knee joint structures. To date,
many efforts have been made to overcome the limitations in
cell harvesting, in vitro culture and implantation techniques.
Novel methods of manufacturing and the emergence of 3D
printing have opened new horizons and in the near future the
growing expectations of clinical applications will likely ap-
pear. Recent developments in cell-based therapeutic methods,
especially those using stem cells, ensure a heterogeneous cell
environment and provide the biological and mechanical stim-
uli that mimic the conditions existing in the native tissue. A
thorough understanding of the biological processes underly-
ing the TE at both cellular and molecular levels will ensure the
safety and effectiveness of these innovations. All these devel-
opments, taken together, may in the future, lead to the suc-
cessful and cost-effective transfer of the TE methods and the
use of novel cell/biomaterial constructs from the bench top to
the bedside.
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